Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Expands Genotyping Deal With GlaxoSmithKline

NEW YORK (GenomeWeb News) – Illumina has expanded the scope of its multi-year genotyping services agreement with GlaxoSmithKline, Illumina said today.
 
Under the new agreement, Illumina will use its Sentrix HumanHap550 BeadChips for a series of whole-genome association studies.
 
As the first study, Illumina will genotype a collection of 2,000 case and control DNA samples provided by GSK for an undisclosed disease.
 
Financial details were not disclosed.